Filing Analysis
Cue Biopharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of recent business highlights and financial performance via an attached press release.
📋 Key Facts
- Report date: August 14, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
- The information under Item 2.02 is furnished, not filed, meaning it is not subject to the liabilities of Section 18 of the Exchange Act.
Cue Biopharma, Inc. announced the appointment of James Ahlers as Chief Financial Officer and Principal Financial Officer, effective July 30, 2026.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- James Ahlers appointed CFO/PFO effective July 30, 2026.
- Annualized base salary is $450,000 with a discretionary annual bonus target of up to 45%.
- Inducement grants include 51,000 nonstatutory stock options (exercise price $30.40) and 25,500 RSUs.
- Equity awards vest in equal quarterly installments over four years subject to continued service.
- Agreement includes a change-in-control provision with accelerated vesting of equity awards.
Cue Biopharma entered into a $50 million private placement agreement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments. The offering includes common stock and pre-funded warrants to fund clinical development and general corporate purposes.
🚩 Red Flags
- Implicit 'going concern' risk mentioned in the cautionary note regarding capital sufficiency.
- Significant dilution potential from the issuance of common stock and pre-funded warrants.
- Registration Rights Agreement requires the company to bear all registration fees and expenses.
📋 Key Facts
- Total gross proceeds of approximately $50.0 million.
- Issuance of 1,418,071 shares of common stock at $33.21 per share.
- Issuance of pre-funded warrants to purchase up to 87,500 shares at a price of $33.209 per warrant.
- Investors include Cormorant Asset Management and Columbia Threadneedle Investments.
- The company agreed to file a registration statement for the resale of these securities within 30 days of closing (expected July 13, 2026).
- Board granted over 1 million RSUs to employees and executives as part of a long-term incentive framework.
Cue Biopharma held a Special Meeting of Stockholders on June 1, 2026, where shareholders approved a new 2026 Stock Incentive Plan and the issuance of common stock related to warrants from a May 2026 licensing transaction and private placement.
📋 Key Facts
- Stockholders approved the Cue Biopharma, Inc. 2026 Stock Incentive Plan.
- Stockholders approved the issuance of common stock upon the exercise of warrants issued in May 2026 in connection with a licensing transaction and private placement.
- Proposal 1 (Warrant issuance) passed with 1,782,133 votes For and 113,311 Against.
- Proposal 2 (2026 Plan) passed with 1,261,296 votes For and 632,474 Against.
Cue Biopharma announced a major overhaul of its corporate governance, including the simultaneous resignation of four board members and the appointment of new directors and key executive officers.
🚩 Red Flags
- Mass exodus of board members: Four directors resigning simultaneously is highly unusual and often indicates internal instability or a strategic pivot.
- Reduction in board size: Shrinking the board from seven to five members may reduce oversight and diversity of governance.
- Multiple 8-K items in a single filing (Item 5.02 and Item 8.01).
📋 Key Facts
- Four board members (Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen) resigned effective May 29, 2026.
- The Board size was reduced from seven directors to five directors effective June 1, 2026.
- Two new directors were appointed on May 30, 2026: Daniel Camardo (Chair of Nominating and Corporate Governance) and Viola Meehan (Chair of Audit Committee).
- Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary on June 1, 2026.
- Michael Meluzio was promoted to Vice President, Principal Accounting Officer, effective June 1, 2026.
Cue Biopharma, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard regulatory disclosure to furnish quarterly performance data to the public.
🚩 Red Flags
- The President and CEO is currently serving as the Interim Principal Financial Officer and Interim Principal Accounting Officer, indicating a vacancy in the company's top financial leadership.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- Press release issued and furnished on May 14, 2026.
- CEO Shao-Lee Lin is currently serving as the Interim Principal Financial Officer and Interim Principal Accounting Officer.
Cue Biopharma entered into a global license agreement (excluding Greater China) with Ascendant Health Sciences for an anti-IgE monoclonal antibody, Ascendant-221. The deal includes a $15 million upfront payment and a securities purchase agreement that guarantees the licensor at least a 7.5% equity stake in the company.
🚩 Red Flags
- Significant potential dilution due to the 'Top-Up' provision guaranteeing the licensor a 7.5% ownership stake regardless of future share counts.
- Liquidated damages clause: Cue must pay 1.0% of the purchase price per 30-day period (up to 6%) if registration statements are not filed or effective on time.
- High milestone-to-upfront ratio ($676.5M vs $15M) suggests heavy back-ended financial obligations that may be difficult for a micro-cap to service without further capital raises.
📋 Key Facts
- Upfront cash payment of $15.0 million to Ascendant Health Sciences Ltd.
- Total potential milestone payments of up to $676.5 million ($205M development/regulatory and $460M commercial).
- Cue Biopharma granted exclusive rights to Ascendant-221 (formerly UB-221) globally, excluding mainland China, Hong Kong, Macau, and Taiwan.
- Securities Purchase Agreement issues pre-funded warrants for 551,724 shares initially, with a 'Top-Up' provision to ensure the licensor owns at least 7.5% of the company's outstanding capital stock.
- Change of control provision accelerates up to $215.0 million in milestone payments if a transaction occurs within 18 months.
- The company must hold a special stockholder meeting within 90 days to approve the share issuance under Nasdaq Listing Rule 5635.
Cue Biopharma, Inc. has announced a 1-for-30 reverse stock split effective April 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The company also explicitly acknowledged an existing 'going concern' determination in its cautionary statements, indicating significant financial distress.
🚩 Red Flags
- Large 1-for-30 reverse stock split ratio, often indicative of severe share price erosion.
- Explicit 'going concern' determination mentioned in the filing.
- Nasdaq delisting threat due to minimum bid price non-compliance.
- History of losses and limited cash reserves acknowledged by management.
- Leadership is currently under an Interim President and CEO.
📋 Key Facts
- A 1-for-30 reverse stock split was approved and filed on April 22, 2026.
- The split becomes effective at 5:00 p.m. ET on April 23, 2026, with post-split trading starting April 24, 2026.
- The action is intended to remediate a Nasdaq minimum bid price deficiency.
- The number of authorized shares and the par value ($0.001) remain unchanged.
- The company's cautionary statements confirm a 'going concern' determination regarding its ability to continue operations beyond the next 12 months.
Cue Biopharma stockholders approved a significant reverse stock split with a ratio between 1-for-30 and 1-for-50. The meeting also finalized the board election following the recent resignation of the company's President and CEO, Usman Azam.
🚩 Red Flags
- Aggressive reverse stock split ratio (up to 1-for-50) typically indicates a struggle to maintain the $1.00 minimum bid price for Nasdaq listing.
- Recent resignation of the President and CEO just prior to the annual meeting.
- High percentage of 'Withheld' votes for certain directors (approximately 37-38% for Verheyen and Broadfoot), suggesting shareholder dissatisfaction.
📋 Key Facts
- Stockholders approved a reverse stock split at a ratio range of 1-for-30 to 1-for-50, with the final ratio to be determined by the Board.
- Former CEO Usman Azam resigned effective March 26, 2026, and Lucinda Warren is currently serving as Interim CEO.
- Six directors were elected, though several received significant 'Withheld' votes, notably Patrick Verheyen (13,387,503 withheld) and Jill Broadfoot (13,683,821 withheld).
- RSM US LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
- The advisory vote on executive compensation was approved with 31,388,709 votes in favor.
Cue Biopharma announced it has achieved a preclinical milestone under its collaboration with Boehringer Ingelheim, triggering a $7.5 million payment expected in May 2026. Despite this cash infusion, the company disclosed in its cautionary statements that it currently has a 'going concern' determination.
🚩 Red Flags
- Explicit 'going concern' determination disclosed in the filing.
- Company states it does not have sufficient capital to continue operations beyond the next twelve months.
- History of losses and limited cash reserves.
📋 Key Facts
- Boehringer Ingelheim approved the selection of the first compound for lead optimization under the April 10, 2025, agreement.
- The milestone triggers a $7.5 million payment to Cue Biopharma.
- The payment is expected to be received in May 2026.
- The collaboration focuses on B cell depletion molecules, including the CUE-501 product candidate.
Cue Biopharma announced the resignation of Usman Azam as President, CEO, and Director, effective March 26, 2026. Lucinda Warren, the current CFO and Chief Business Officer, has been appointed Interim President and CEO effective March 27, 2026.
🚩 Red Flags
- The CEO's resignation from both management and the Board is effective immediately, just weeks before the April 13, 2026, Annual Meeting of Stockholders.
- The Interim CEO's equity incentive is explicitly tied to a 'specified financing milestone,' suggesting an immediate need for capital and potential upcoming dilution.
📋 Key Facts
- Usman Azam resigned as CEO and from the Board of Directors effective March 26, 2026.
- Lucinda Warren appointed Interim CEO while continuing her roles as CFO and Chief Business Officer.
- Warren's compensation includes a $525,000 base salary and a $10,000 monthly supplemental payment for the interim period.
- Warren is eligible for a stock option grant representing approximately 1.0% of outstanding shares upon the achievement of a 'specified financing milestone.'
- Azam will receive a lump sum severance of $232,500, representing 3 months of base salary and 25% of his target 2026 bonus.
Cue Biopharma, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the period ended December 31, 2025.
- The report was filed on March 16, 2026, under Item 2.02.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes a press release as Exhibit 99.1 and was signed by CEO Usman Azam.
Cue Biopharma, Inc. announced the date for its 2026 Annual Meeting of Stockholders, scheduled for April 13, 2026. The filing outlines deadlines for stockholder proposals and director nominations in accordance with company bylaws and SEC universal proxy rules.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is set for April 13, 2026.
- Stockholder proposals under Rule 14a-8 must be received by February 28, 2026, to be considered for inclusion in proxy materials.
- The deadline for director nominations and other matters under the company's Bylaws is February 28, 2026.
- Compliance with Rule 14a-19 (universal proxy rule) requires notice by February 28, 2026, for stockholders intending to solicit proxies for non-company nominees.
Cue Biopharma, Inc. announced the appointment of Lucinda Warren as Chief Financial and Business Officer, effective February 9, 2026. Ms. Warren, who has served as Chief Business Officer since September 2024, will also assume the duties of principal financial officer and principal accounting officer.
📋 Key Facts
- Lucinda Warren appointed as Chief Financial and Business Officer effective February 9, 2026.
- Ms. Warren assumes roles of Principal Financial Officer and Principal Accounting Officer.
- Ms. Warren previously served as Chief Business Officer since September 2024.
- No additional compensation or material changes to employment agreement were made for this appointment.
- Ms. Warren brings over 30 years of experience, including a decade at Johnson & Johnson.
Cue Biopharma, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC for a public offering of common stock and warrants to raise approximately $8.9 million in net proceeds. The offering includes significant pre-funded warrants which could lead to substantial dilution.
🚩 Red Flags
- Significant potential dilution due to large number of warrants and pre-funded warrants.
- Extremely low share price ($0.28) suggests a highly distressed capital structure.
- Explicit mention in risk factors regarding the need to remediate a current 'going concern' determination.
- High reliance on upcoming milestone payments from ImmunoScape Pte. Ltd. to sustain operations.
📋 Key Facts
- Underwriting agreement signed on December 19, 2025.
- Offering includes 12,500,000 Firm Shares and accompanying warrants at $0.28 per unit.
- Includes pre-funded warrants for an additional 23,214,286 shares of common stock.
- Net proceeds estimated at approximately $8.9 million (up to $10.3 million if underwriters exercise the option).
- The offering is being conducted via a shelf registration statement on Form S-3 filed May 9, 2023.
- Estimated cash runway extended into the first quarter of 2027 based on current plans.
Cue Biopharma, Inc. filed an 8-K to make its updated corporate presentation publicly available via its website. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The company released an updated corporate presentation on November 24, 2025.
- The filing was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
Cue Biopharma, Inc. announced the departure of its Chief Medical Officer, Dr. Matteo Levisetti, effective November 28, 2025. The separation includes a severance package consisting of nine months of base salary and prorated bonus.
🚩 Red Flags
- Departure of a key C-suite officer (Chief Medical Officer) can disrupt clinical development timelines in biopharma companies.
📋 Key Facts
- Dr. Matteo Levisetti is departing from his role as Chief Medical Officer.
- The Separation Date is scheduled for November 28, 2025.
- Severance includes a lump sum cash payment of $556,837.60 (less taxes/withholdings).
- Severance package covers nine months of base salary plus a prorated portion of the 2025 annual bonus.
- The company will pay full COBRA premiums for up to nine months or until new employment is secured.
Cue Biopharma, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2025. The filing serves as a formal announcement of results of operations and financial condition.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes Exhibit 99.1 (Press Release) regarding financial results.
Cue Biopharma entered into a Collaboration and License Agreement with ImmunoScape Pte. Ltd. (IMSCP) for the CUE-100 Series molecules, granting IMSCP co-exclusive development and exclusive commercial rights. The deal includes significant upfront cash, milestone payments, and equity in IMSCP.
🚩 Red Flags
- The company explicitly mentions a current 'going concern' determination in its cautionary note, indicating insufficient capital to continue operations beyond twelve months.
- Agreement includes a termination clause allowing IMSCP to exit with only 60 days' notice, creating significant revenue/partnership risk.
📋 Key Facts
- Effective date of agreement: November 6, 2025.
- Company received $5 million aggregate in Q4 2025 upon exercise of the option.
- IMSCP to pay an additional $5 million by December 2025.
- An additional $5 million time-based payment due before the first anniversary of the option exercise.
- Cue Biopharma receives 40% equity in IMSCP plus warrants upon future dilution events.
- Royalty structure: High single-digit on global net sales; low-to-mid double-digit on sublicensing income.
- IMSCP retains the ability to terminate the agreement with 60 days' notice.
Cue Biopharma announced a leadership transition where Dr. Usman Azam will succeed Daniel R. Passeri as President and CEO, effective September 29, 2025. The filing details the new CEO's compensation package and the separation/advisory terms for the outgoing CEO.
🚩 Red Flags
- Significant cash severance payment ($838,750) to the outgoing CEO.
- Performance-based equity grants for both new and former executives are tied to 'specified financing milestones', which may indicate upcoming capital raises or liquidity pressure.
📋 Key Facts
- Usman Azam appointed President and CEO effective September 29, 2025.
- Dr. Azam to receive $620,000 annual base salary and a target discretionary bonus of up to 50% of base salary.
- Azam granted 1,875,000 time-based stock options and 375,000 performance-based stock options.
- Daniel R. Passeri is retiring/resigning as CEO effective September 29, 2025, but will serve as a strategic advisor until at least March 30, 2026.
- Passeri to receive $838,750 in cash severance and accelerated vesting (12 months) of existing equity awards.
- Passeri granted an option for up to 375,000 shares subject to a specified financing milestone.
Cue Biopharma, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes Exhibit 99.1 containing the press release with financial results.
Cue Biopharma entered into a Second Amendment to its License Agreement with MIL 40G, LLC on June 30, 2025. The amendment reduces monthly rental costs and extends the license term through April 2028.
🚩 Red Flags
- The reduction in rental rates may indicate cash flow constraints or a need to extend runway by reducing monthly burn.
📋 Key Facts
- Effective date of Second Amendment: June 30, 2025.
- Monthly rental rate reduced from $235,883.98 to $147,545.69.
- The new rate is subject to a 4% increase on April 15, 2027.
- License term extended from April 14, 2026, to April 14, 2028.
- Licensor granted a partial credit of $44,169.14 for rent paid at the higher rate in June 2025.
Cue Biopharma announced the resignation of its Chief Financial Officer, Kerri-Ann Millar, effective June 13, 2025. In response, CEO Daniel R. Passeri will assume the role of principal financial and accounting officer on an interim basis.
🚩 Red Flags
- Sudden departure of the Chief Financial Officer (CFO) creates leadership instability in a critical finance role.
- CEO assuming interim CFO duties suggests a temporary gap in specialized financial oversight.
- Significant increase in authorized shares (from 210M to 310M) often precedes potential dilutive equity offerings.
📋 Key Facts
- CFO Kerri-Ann Millar is resigning effective June 13, 2025.
- CEO Daniel R. Passeri to serve as interim CFO/Principal Financial Officer starting June 13, 2025.
- Jill Broadfoot appointed to the Board and elected as Chair of the Audit Committee.
- Stockholders approved an increase in authorized shares from 210M to 310M total capital stock (common stock increased from 200M to 300M).
- Stockholders approved the 2025 Stock Incentive Plan.
- RSM US LLP was ratified as the independent registered public accounting firm for FY2025.
Cue Biopharma, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of financial results for the quarter ending March 31, 2025.
- Financial results were announced via a press release dated May 12, 2025 (Exhibit 99.1).
- The report was signed by CEO Daniel R. Passeri.
Cue Biopharma announced a significant underwritten public offering of common stock and warrants to raise approximately $18.0 million in net proceeds. The offering is intended to extend the company's cash runway into Q2 2026, following a recent collaboration agreement with Boehringer Ingelheim.
🚩 Red Flags
- Significant dilution: The offering involves over 24 million total shares/pre-funded warrants, which is substantial relative to typical micro-cap structures.
- Warrant overhang: Issuance of a large number of common stock and pre-funded warrants can lead to future dilution and downward price pressure.
- Historical 'going concern' issues mentioned in the cautionary note regarding capital sufficiency.
📋 Key Facts
- Underwritten public offering of 13,530,780 shares and accompanying warrants.
- Offering includes pre-funded warrants to purchase 11,469,216 shares at a combined price of $0.789 per share.
- Estimated net proceeds from the offering are approximately $18.0 million.
- The company reported estimated cash and cash equivalents of $13.1 million as of March 31, 2025.
- Expected closing date for the offering is on or about April 16, 2025.
- Company expects to fund operations into the second quarter of 2026 using these proceeds and a $12.0 million upfront payment from Boehringer Ingelheim.
Cue Biopharma entered into a significant Collaboration and License Agreement with Boehringer Ingelheim (BI) to develop B cell depletion therapies, including CUE-501. The deal includes an upfront payment of $12 million and potential milestone payments totaling up to $345 million.
🚩 Red Flags
- Exclusivity restriction: The Company is prohibited from developing or commercializing any molecule for applications in B cell depletion during the Research Term, limiting its independent pipeline scope in this therapeutic area.
📋 Key Facts
- Entered into Collaboration and License Agreement with Boehringer Ingelheim (BI) on April 10, 2025.
- Focus is on CUE-501 product candidate for autoimmune diseases and other B cell depletion molecules.
- Upfront payment of $12.0 million to Cue Biopharma.
- Potential milestone payments totaling approximately $345.0 million based on research, development, and commercial success.
- BI receives an exclusive, royalty-bearing, worldwide, sublicensable license for Licensed Products.
- Cue Biopharma is prohibited from developing/commercializing any B cell depletion molecules during the Research Term.
- Amendment to Einstein License Agreement was executed to allow sublicensing rights to BI.
Cue Biopharma, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Cue Biopharma, Inc. announced the appointment of Pasha Sarraf to its Board of Directors on March 10, 2025. The appointment follows a recommendation from the Corporate Governance and Nominating Committee.
📋 Key Facts
- Pasha Sarraf appointed to the Board of Directors on March 10, 2025.
- Compensation includes an option to purchase 48,800 shares of common stock.
- Stock options vest over three years: one-third at the one-year anniversary and the remainder in eight equal quarterly installments.
- The appointment is subject to the Company's standard indemnification agreement.
Cue Biopharma, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing was made on November 14, 2024.
- The report pertains to Item 2.02: Results of Operations and Financial Condition.
- Financial results were announced via a press release dated November 14, 2024 (Exhibit 99.1).
Cue Biopharma, Inc. successfully held a special meeting on October 8, 2024, where stockholders approved an amendment to increase the authorized number of shares of capital stock and common stock.
🚩 Red Flags
- Significant increase in authorized share count (doubling common stock) often precedes dilutive equity offerings or warrants exercises.
📋 Key Facts
- Stockholders approved increasing total authorized capital stock from 110,000,000 to 210,000,000 shares.
- Stockholders approved increasing authorized common stock from 100,000,000 to 200,000,000 shares.
- The amendment was passed with 29,291,818 votes 'For' and 7,409,258 votes 'Against'.
- A proposal to adjourn the meeting for further proxy solicitation was unnecessary as a quorum was present and sufficient votes were obtained.
Cue Biopharma entered into a Second Amendment to its Loan and Security Agreement with Silicon Valley Bank on October 2, 2024. The amendment modifies cash maintenance requirements previously established in the original February 2022 agreement.
🚩 Red Flags
- Modification of restrictive covenants suggests the company may have struggled to meet the previous $20M minimum cash threshold at SVB specifically.
- Shift in liquidity management requirements often indicates negotiation due to tightening capital constraints or changes in banking relationships/regulations.
📋 Key Facts
- Effective Date of amendment: October 2, 2024.
- The Second Amendment removes the requirement to maintain a minimum of $20,000,000 in cash at SVB (the 'Threshold Amount').
- New cash requirement: The Company must maintain unrestricted and unencumbered cash equal to the lesser of the Threshold Amount ($20M) or 100% of its total consolidated cash across all financial institutions.
- The agreement is with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.
Cue Biopharma, Inc. entered into an underwriting agreement on September 26, 2024, for a public offering of common stock and warrants to raise approximately $10.7 million in net proceeds. The offering includes both standard shares and pre-funded warrants at a combined price of roughly $0.50 per share.
🚩 Red Flags
- Significant dilution: The issuance of over 11 million shares and nearly 12.5 million pre-funded warrants represents substantial potential dilution for existing shareholders.
- Low share price: Offering price is $0.50, indicating a micro-cap/penny stock profile with high volatility risk.
- Warrant overhang: Large number of warrants (over 6 million total) will likely lead to further dilution upon exercise.
📋 Key Facts
- Underwriting agreement signed with Oppenheimer & Co. Inc. on September 26, 2024.
- Offering consists of 11,564,401 common shares and accompanying warrants, plus pre-funded warrants for 12,435,599 shares.
- Combined offering price is $0.50 per share/pre-funded warrant (with a $0.001 exercise price for the pre-funded portion).
- Estimated net proceeds of approximately $10.7 million.
- Expected closing date on or about September 30, 2024.
- The offering is being conducted via a shelf registration statement (Form S-3) filed May 9, 2023.
Cue Biopharma, Inc. announced the resignation of Michael J. Fox from its Board of Directors and all associated committees, effective August 28, 2024.
🚩 Red Flags
- None identified; the filing includes standard language clarifying no disagreements exist between the director and the company.
📋 Key Facts
- Michael J. Fox resigned as a member of the Board of Directors on August 28, 2024.
- The resignation is effective immediately (August 28, 2024).
- The company explicitly stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Cue Biopharma, Inc. received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has an initial 180-day period to regain compliance before facing potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential for mandatory reverse stock split to regain compliance
- Stock price has been consistently below $1.00 (penny stock territory)
📋 Key Facts
- Received deficiency letter from Nasdaq on August 15, 2024.
- Violation of Nasdaq Listing Rule 5550(a)(2) due to stock closing below $1.00 for 30 consecutive business days.
- Initial compliance period expires February 11, 2025 (180 calendar days).
- To regain compliance, the bid price must close at or above $1.00 for at least 10 consecutive business days.
- A second 180-day extension may be available if the company meets other listing standards and intends to cure via a reverse stock split.
Cue Biopharma is undergoing significant organizational restructuring, including a 25% workforce reduction and strategic prioritization of autoimmune programs. To preserve capital, the CEO has agreed to a 50% salary reduction and executive officers are forgoing 2023 bonuses.
🚩 Red Flags
- Significant workforce reduction (25%) indicating distress or aggressive cost-cutting.
- Executive compensation cuts and bonus forfeitures suggest liquidity constraints.
- Cash runway only extends to mid-year 2025, implying a need for significant financing within the next 6-9 months.
📋 Key Facts
- Company implementing an approximate 25% reduction in workforce.
- CEO Daniel R. Passeri reducing his 2024 annual base salary by 50%, effective immediately.
- Executive officers are forgoing any annual bonus earned for 2023 performance.
- The restructuring aims to extend the company's cash runway into mid-year 2025.
- Strategic focus is shifting toward autoimmune programs.
Cue Biopharma, Inc. announced the appointment of Michael J. Fox to its Board of Directors and Compensation Committee on June 5, 2024. The filing also reports the results of the company's 2024 Annual Meeting of Stockholders.
📋 Key Facts
- Michael J. Fox appointed to the Board of Directors and the Compensation Committee effective June 5, 2024.
- Mr. Fox granted an option to purchase 48,800 shares of common stock, vesting over three years (1/3 at one-year anniversary; remainder in eight equal quarterly installments).
- Stockholders ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Six nominees were elected to the Board: Daniel R. Passeri, Frank Morich, Frederick Driscoll, Pamela Garzone, Peter A. Kiener, and Patrick Verheyen.
- A non-binding advisory proposal on executive compensation was approved by stockholders.
Cue Biopharma, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended March 31, 2024. The filing is a standard regulatory requirement for reporting results of operations and financial condition.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The company furnished Exhibit 99.1 containing the press release regarding financial results.